APLMW Company Profile and Key Details

Average 10-day trading volume of 4.25 thousand shares is below the 3-month average of 95.98 thousand, indicating normal recent market interest.

Apollomics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.16. This means the shares are trading below this model’s fair value.

The stock is currently trading near its 52-week low $0.01 and $0.03. With a market capitalization of about $171.45 million, Apollomics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.07). Key stats such as the average daily volume over the past year has been around 80.60 thousand shares, volume is running light vs its 52-week average. Headquartered in Foster City, CA, Apollomics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Hung-Wen Chen, the company employs approximately 14 people and listed since March 30, 2023. Apollomics, Inc. functions as a clinical-phase biotechnology enterprise, concentrating its efforts on discovering and advancing novel cancer treatments to meet crucial, underserved patient requirements.

Our AI price prediction model suggests that Apollomics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Apollomics, Inc. trading at a premium to the broader market with a P/E of -2.96.

Apollomics, Inc. trades at a P/E ratio of -2.96, slightly below the S&P 500 average, with a price-to-sales ratio of 5.78 and a price-to-book ratio of -2.96 indicating negative book value, which may reflect financial stress. The P/FCF stands at -4.74, also below market averages.